Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1811698 | 0.90 | NPC1 (0.63) | NPC1RAB9ADNMT3AGAALMNA | |
| SCHEMBL1812144 | 0.89 | MEN1 (0.65) | GAALMNAMEN1KMT2APOLB | |
| SCHEMBL1814208 | 0.87 | GAA (0.55) | DNMT3AGAALMNAMEN1KMT2A | |
| SCHEMBL1813399 | 0.83 | GAA (0.66) | NPC1RAB9AGAALMNAMEN1 | |
| SCHEMBL6267575 | 0.79 | CYP1A2 (0.65) | NPC1RAB9AGAALMNAMEN1 | |
| SCHEMBL19579563 | 0.79 | SMN1; SMN2 (0.67) | NPC1RAB9AGAALMNAMEN1 | |
| SCHEMBL23832296 | 0.77 | HPGD (0.58) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL17205863 | 0.77 | CA1 (0.62) | LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5753081 | 0.77 | NPC1 (0.79) | NPC1RAB9AGAAMEN1KMT2A | |
| SCHEMBL1264805 | 0.76 | NPC1 (0.56) | NPC1RAB9AGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237678-A1 | N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-09-29 | — | — | US | claimed |
| US-20090156682-A1 | N-(1-Methyl-2Phenylethyl)Benzamide Derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-18 | — | — | US | claimed |
| EP-1960350-A1 | NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-08-27 | — | — | EP | claimed |
| WO-2007060162-A1 | NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2007-05-31 | — | — | WO | claimed |
| US-8314269-B2 | N-(1-methyl-2phenylethyl)benzamide derivatives | BAYER CROPSCIENCE AG (DE) | 2012-11-20 | — | — | US | disclosed |
| US-20110237678-A1 | N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-7951973-B2 | N-(1-methyl-2Phenylethyl)benzamide derivatives | BAYER CROPSCIENCE AG (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20090156682-A1 | N-(1-Methyl-2Phenylethyl)Benzamide Derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-1960350-A1 | NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007060162-A1 | NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156682-A1 | N-(1-Methyl-2Phenylethyl)Benzamide Derivatives | CYP51A1, CYP1A2, CYP1A1 | NPC1 175/4885RAB9A 1825/4885DNMT3A 269/4885 |
| US-20110237678-A1 | N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES | CYP51A1, CYP1A2, CYP1A1 | NPC1 184/4885RAB9A 1885/4885DNMT3A 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.